Announcements Trials
Browse Landscape

Phase

Phase 1/2 2

Status

Terminated 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 4Head & Neck 2

Conditions

Squamous Cell Carcinoma of Head and Neck 5Head and Neck Neoplasms 3Hereditary Sensory and Autonomic Neuropathies 2Head and Neck Squamous Cell Cancer 2Recurrence 1Oropharyngeal Neoplasms 1Neoplasms 1Carcinoma, Squamous Cell 1Carcinoma 1Breast Neoplasms 1

Interventions

Fulvestrant 2Alpelisib 2tipifarnib 1ribociclib 1palbociclib 1exemestane 1abemaciclib 1Tamoxifen 1STX-478 1SF 1126 1Panobinostat 1PX-866 1Metformin 1Letrozole 1Imlunestrant 1Everolimus 1Docetaxel 1Cetuximab 1Anastrozole 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Hereditary Sensory and Autonomic Neuropathies × Alpelisib × Head & Neck × Clear all
NCT04997902 2025-12-23

Combination Trial of Tipifarnib and Alpelisib in Adult Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC)

Kura Oncology, Inc.

Phase 1/2 Completed
45 enrolled
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Hereditary Sensory and Autonomic Neuropathies, Recurrence

NCT01602315 2020-12-29

A Phase Ib/II Study of BYL719 and Cetuximab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Novartis

Phase 1/2 Terminated
179 enrolled 38 charts
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Hereditary Sensory and Autonomic Neuropathies

Data powered by HemOnc (CC BY 4.0) Colophon âš¡